Retinitis pigmentosa (RP) is a rare genetic disorder marked by retinal degeneration, progressive vision loss, and eventual blindness. There are no approved pharmacotherapies for RP, and current disease management options comprise nutritional supplementation (e.g., vitamin A, omega-3 fatty acids), off-label treatments for comorbidities (e.g., carbonic anhydrase inhibitors), and approved retinal prosthetic devices (i.e., Second Sight’s Argus II, Retinal Implant AG’s Alpha IMS). Significant unmet clinical need and commercial opportunity exists for medications with disease-modifying potential. The RP clinical pipeline is robust and diverse, comprising gene therapy, stem-cell therapy, and other approaches such as neuroprotection and stimulation of neurogenesis. However, the majority of these therapies are in early phases of development and face many scientific, clinical, and developmental hurdles in order to obtain regulatory approval for the treatment of RP.
Questions Answered
How will the size of the RP population change through 2026? What percentage of the RP population receives drug treatment?
What are the key drug targets and technologies emerging from basic and clinical research in RP? Which emerging therapies have RP experts intrigued or optimistic? How would new therapies influence management of RP patients?
The RP pipeline comprises various mechanisms of action and technologies. How are these therapies being evaluated, and which are likely to launch by 2026? What commercial impact will they have on the RP market?
Product Description
Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.